|
|
||||||||||||||||||||||||||||||||||||||||||||
 
By The Online Investor Staff, updated Mon., Nov. 17, 4:13 AM
|
|||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #12 of 25 |
Slide #12. Biohaven Ltd. — Secondary Offering
Company:
Biohaven Ltd. (NYSE:BHVN)
Date announced:
11/11/2025
Shares Offered:
23,333,334
Date of Pricing:
11/12/2025
Price Per Share:
$7.50
Secondary Offering Details:
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $150 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Biohaven intends to use the net proceeds received from the offering for general corporate purposes. -updated 11/12- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 23,333,334 of its common shares at a price to the public of $7.50 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 common shares at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $175 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. The offering is expected to close on November 13, 2025, subject to satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for immunology, neuroscience, and oncology. Its programs include Kv7 ion channel modulation for epilepsy and mood disorders, extracellular protein degradation for immunological diseases, TRPM3 antagonism for migraine and neuropathic pain, TYK2/JAK1 inhibition for neuroinflammatory disorders, glutamate modulation for OCD and SCA, myostatin inhibition for neuromuscular and metabolic diseases like SMA and obesity, and antibody recruiting, bispecific molecules, and ADCs for cancer. Troriluzole is a new chemical entity and tripeptide prodrug of riluzole.
BHVN SEC Filing Email Alerts Service
Open the BHVN Page at The Online Investor »
|
|||||||||||||||
Open the BHVN Page at The Online Investor (in a new window) »
 Free BHVN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.47 out of 4) 69th percentile
(ranked higher than approx. 69% of all stocks covered)
Analysts' Target Price: BHVN Stock Forecast Based on Zacks ABR data; via Quandl.com |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2025, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.